Effect of supplementation in treatment of patients with multiple sclerosis

INTERVENTION: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for 12 weeks orally. Intervention 1: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for 12 weeks orally. Intervention 2: Intervention group: Probiotic capsule containing four strains of Lactobacillus acidophilus (2×109 CFU/g), Lactobacillus casei (2×109 CFU/g), Bifidobacterium bifidum (2×109 CFU/g) and Lactobacillus fermentum (2×109 CFU/g) (Tak Gen Zist, Tehran, Iran), daily, for 12 weeks orally. Intervention group: Probiotic capsule containing four strains of Lactobacillus acidophilus (2×109 CFU/g), Lactobacillus casei (2×109 CFU/g), Bifidobacterium bifidum (2×109 CFU/g) and Lactobacillus fermentum (2×109 CFU/g) (Tak Gen Zist, Tehran, Iran), daily, for 12 weeks orally. Treatment ‐ Drugs CONDITION: Multiple sclerosis Multiple sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: Interleukin 6. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR. Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR. SECONDARY OUTCOME: PPAR‐?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR. INCLUSION CRITERIA: INCLUSION CRITERIA: Patients with multiple sclerosis; aged 20 to 60 years. Exclusion criteria: Unwillingness to cooperate.